Every 8-K that PMV Pharmaceuticals, Inc (PMVP) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow PMVP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PMVP filings page.
PMV Pharmaceuticals, Inc. (PMVP) priced an underwritten public offering of (i) 22,055,000 shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 19,900,000 shares, and (ii) accompanying warrants to purchase 41,955,000 shares of common stock. Each share plus accompanying warrant is priced at $1.21, and each pre-funded warrant plus accompanying warrant at $1.20999, reflecting a $0.00001 pre-funded warrant exercise price. The company expects gross proceeds of about $50.8 million and net proceeds of about $47.0 million, and plans to use them, together with existing cash, primarily to fund late-stage clinical development, regulatory submission and commercialization preparation for rezatapopt. Based on its current plan, PMV believes this financing, together with existing cash, will fund operations into the first quarter of 2028. The accompanying warrants are immediately exercisable at $1.21 per share for five years and include a reset mechanism and potential Mandatory Exercise tied to FDA acceptance of the company’s NDA for rezatapopt.
PMV Pharmaceuticals, Inc. (PMVP) reported updated interim ovarian cancer data from the Phase 2 pivotal portion of its registrational PYNNACLE trial of rezatapopt monotherapy in TP53 Y220C advanced solid tumors. The trial uses a 2000 mg once-daily oral dose and includes platinum-resistant/refractory ovarian cancer patients, for whom enrollment for the primary analysis has been completed.
As of a May 14, 2026 data cutoff, rezatapopt continued to show a favorable and consistent safety and tolerability profile across cohorts, with mostly Grade 1–2 treatment-related adverse events and a 5% discontinuation rate due to treatment-related events; the ovarian cancer cohort safety profile was similar to the overall population. PMV Pharma received FDA feedback that continues to support its strategy to seek accelerated approval for rezatapopt in platinum-resistant/refractory TP53 Y220C ovarian cancer based on the Phase 2 portion of PYNNACLE and anticipates submitting a New Drug Application in the first quarter of 2027. The company plans to present updated data from all Phase 2 pivotal cohorts, including primary analysis data from the ovarian cohort, at a medical conference in the fourth quarter of 2026.
PMV Pharmaceuticals reported second quarter 2026 results and a key clinical milestone for its lead asset rezatapopt. Enrollment for the primary analysis of platinum-resistant/refractory ovarian cancer patients in the Phase 2 monotherapy portion of the registrational PYNNACLE trial has been completed. The company plans to submit a New Drug Application for rezatapopt for platinum-resistant/refractory ovarian cancer in the first quarter of 2027 and notes existing Fast Track and Orphan Drug Designations.
PMV Pharma had $79.4 million in cash, cash equivalents and marketable securities as of June 30, 2026, and expects this to fund operations through the second quarter of 2027. For the quarter, net loss was $18.1 million versus $21.2 million a year earlier, driven mainly by lower contract research organization and finance support costs. Research and development expenses were $14.7 million compared with $18.4 million, and general and administrative expenses were $4.2 million compared with $4.5 million, reflecting cost reductions as the company advances its precision oncology pipeline targeting TP53 Y220C mutations.
PMV Pharmaceuticals, Inc. reported the results of its 2026 virtual annual meeting of stockholders. Stockholders elected two Class III directors: David H. Mack, Ph.D. received 15,693,907 votes for and 6,248,461 withheld, while Laurie Stelzer received 11,261,111 votes for and 10,681,257 withheld. Each will serve until the 2029 annual meeting, subject to earlier death, resignation or removal.
Stockholders approved, on a non-binding advisory basis, the compensation of the company’s named executive officers, with 15,015,578 votes for, 6,468,718 against, 458,072 abstentions and 6,975,412 broker non-votes. They also ratified the selection of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, by 28,379,108 votes for, 536,302 against and 2,370 abstentions.
PMV Pharmaceuticals reported first quarter 2026 results and highlighted progress for its lead candidate rezatapopt. The company ended March 31, 2026 with $93.5 million in cash, cash equivalents, and marketable securities, which it expects will fund operations into the end of the second quarter of 2027. Net loss was $18.0 million, or $0.34 per share, roughly in line with the prior year as both research and development and general and administrative expenses declined.
Clinically, updated Phase 2 PYNNACLE data in platinum‑resistant/refractory ovarian cancer with TP53 Y220C mutations showed an overall response rate of 44% (32/72) by RECIST 1.1, rising to 46% (34/74) including two additional unconfirmed partial responses, with a median response duration of 8.2 months. Rezatapopt received U.S. FDA Orphan Drug Designation for TP53 Y220C‑positive ovarian, fallopian tube, and primary peritoneal cancers, and PMV plans to submit a New Drug Application for this ovarian cancer indication in the first quarter of 2027.
PMV Pharmaceuticals, Inc. reported full-year 2025 results and highlighted progress for its lead p53 reactivator, rezatapopt. The Phase 2 PYNNACLE trial showed a 34% overall response rate among 103 evaluable patients and a 46% response rate in 48 ovarian cancer patients, with responses lasting around 8 months.
Rezatapopt received U.S. FDA Orphan Drug Designation for TP53 Y220C–positive ovarian, fallopian tube, and primary peritoneal cancers, and Phase 1 data were published in the New England Journal of Medicine. As of December 31, 2025, PMV held $112.9 million in cash, cash equivalents, and marketable securities, providing expected cash runway to the end of the second quarter of 2027.
Net loss for 2025 was $77.7 million versus $58.7 million in 2024, driven mainly by higher research and development spending of $69.9 million. General and administrative expenses decreased to $16.3 million from $26.9 million, reflecting lower facility and personnel costs after prior-year restructuring.
PMV Pharmaceuticals (PMVP) furnished an 8-K announcing financial results for the third quarter ended September 30, 2025. The company issued a press release on November 12, 2025, which is attached as Exhibit 99.1 and incorporated by reference.
The company states the information under Item 2.02, including Exhibit 99.1, is being furnished and not deemed filed under the Exchange Act, limiting potential Section 18 liability and incorporation unless specifically referenced.
PMV Pharmaceuticals, Inc. (PMVP) filed an 8-K reporting a material event: the company issued a press release and hosted an investor webinar on September 10, 2025 to present interim monotherapy data for rezatapopt from the PYNNACLE Phase 2 trial in multiple solid tumors with a TP53 Y220C mutation. The press release is attached as Exhibit 99.2 and is incorporated by reference into the filing.
The filing notes the public dissemination of clinical interim results and the webinar but does not include the data tables or numerical results within the 8-K text itself. No financial results, enrollment counts, regulatory actions, or next-step timelines are disclosed in the provided excerpt.